Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach

Allogene, the next-gen CAR-T company out to prove that their off-the-shelf approach to treating blood cancers is just as good as the autologous pioneers — or potentially even better — is out with a fresh set of data in the leadup to ASCO 21 which they believe can go a…